Details

Autor(en) / Beteiligte

• Huh, Hee Jae
• Kim, Su-Young
• Shim, Hyang Jin
• Kim, Dae Hun
• Yoo, In Young
• Kang, On-Kyun
• Ki, Chang-Seok
• Shin, So Youn
• Jhun, Byung Woo
• Shin, Sung Jae
• Daley, Charles L
• Koh, Won-Jung
• Lee, Nam Yong
• Land, Geoffrey A.

Titel

GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance

Ist Teil von

• Journal of clinical microbiology, 2019-08, Vol.57 (8)

Ort / Verlag

United States: American Society for Microbiology

Erscheinungsjahr

2019

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• We evaluated the GenoType NTM-DR (NTM-DR) line probe assay for identifying complex (MAC) species and subspecies and for determining clarithromycin and amikacin resistance. Thirty-eight reference strains and 145 clinical isolates (58 MAC and 87 isolates), including 54 clarithromycin- and/or amikacin-resistant strains, were involved. The performance of the NTM-DR assay in rapid identification was evaluated by comparison with results of multigene sequence-based typing, whereas performance in rapid detection of clarithromycin and amikacin resistance was evaluated by comparison with sequencing of the (41), , and genes and drug susceptibility testing (DST). The accuracies of MAC and (sub)species identification were 92.1% (35/38) and 100% (145/145) for the 38 reference strains and 145 clinical isolates, respectively. Three MAC strains other than were found to cross-react with the probe in the assay. Regarding clarithromycin resistance, NTM-DR detected mutations in 52 isolates and yielded 99.3% (144/145) and 98.6% (143/145) concordant results with sequencing and DST, respectively. NTM-DR sensitivity and specificity in the detection of clarithromycin resistance were 96.3% (52/54) and 100% (91/91), respectively. The NTM-DR yielded accurate (41) genotype results for all 87 isolates. Regarding amikacin resistance, NTM-DR detected mutations in five isolates and yielded 99.3% (144/145) and 97.9% (142/145) concordant results with sequencing and DST, respectively. Our results indicate that the NTM-DR assay is a straightforward and accurate approach for discriminating MAC and (sub)species and for detecting clarithromycin and amikacin resistance mutations and that it is a useful tool in the clinical setting.